Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Moleculin Biotech Inc

MBRX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.61

▲ +7.16%

Market Cap $11.92M · Vol 357.21K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.92M

Micro Cap

Div Yield

N/A

EPS Growth

+85.45%

YoY

RSI (14)

12.11

Momentum

Beta

1.91

vs Market

52W High

$17.06

96.41% below

52W Low

$0.17

269.24% above

Volume

357.21K

Avg 213.03K

P/B

0.71

Price-to-book

ROE

N/A

Return on equity

Free Float

93.59%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Moleculin Biotech Inc (MBRX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MBRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+49.50%

-72.91%

-72.17%

-85.89%

YTD

-81.50%

-96.22%

-99.73%

-99.95%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-33,560,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-171.88% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.71
P/FCF	N/A
EPS Growth	+85.45%
Outstanding Shares	19.48M

Technical Indicators

50-Day SMA	$2.01
200-Day SMA	$3.87
RSI (14)	12.11
Beta	1.91
52-Week High	$17.06
52-Week Low	$0.17

Volume Today	357.21K
Avg Daily Volume (30D)	213.03K
Relative Volume	1.68x
Volatility (10D)	93.98
Volatility (30D)	315.40
Free Float	93.59%

Analyst Consensus

BUY

Current Price $0.61

Mean Target $18.33

52W Low$0.17 52W High$17.06

Current

Target

$0.17 $17.06

Current Analyst target

+2,894.66% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00B9T47N7

ISINUS60855D4088

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).